Simulations Plus (NASDAQ:SLP) Issues FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 1.070-1.200 for the period, compared to the consensus earnings per share estimate of 0.900. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $90.7 million. Simulations Plus also updated its FY25 guidance to $1.07-$1.20 EPS.

Wall Street Analysts Forecast Growth

SLP has been the topic of a number of research reports. Stephens initiated coverage on shares of Simulations Plus in a report on Friday, November 15th. They issued an “overweight” rating and a $39.00 target price on the stock. BTIG Research lowered their target price on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. StockNews.com lowered Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Finally, William Blair restated an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Simulations Plus currently has an average rating of “Moderate Buy” and an average price target of $51.40.

Simulations Plus Stock Performance

Shares of Simulations Plus stock traded up $1.29 on Tuesday, reaching $30.39. The stock had a trading volume of 492,972 shares, compared to its average volume of 303,448. The business’s 50-day moving average price is $29.78 and its two-hundred day moving average price is $34.16. The stock has a market cap of $610.38 million, a P/E ratio of 62.02 and a beta of 0.80. Simulations Plus has a fifty-two week low of $27.07 and a fifty-two week high of $51.22.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The company had revenue of $18.70 million during the quarter, compared to analysts’ expectations of $19.73 million. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The business’s quarterly revenue was up 19.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.18 earnings per share. As a group, equities analysts forecast that Simulations Plus will post 1.1 earnings per share for the current fiscal year.

Insider Buying and Selling at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $31.76, for a total transaction of $635,200.00. Following the sale, the director now directly owns 3,442,584 shares of the company’s stock, valued at $109,336,467.84. This trade represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 19.40% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.